Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23

Breast Cancer Research and Treatment

Volumn 86, Issue 2, 2004, Pages 153-164

  Land, Stephanie R ^a,b   Kopec, Jacek A ^c   Yothers, Greg ^a   Anderson, Stewart ^a,b   Day, Richard ^b   Tang, Gong ^a,b   Ganz, Patricia A ^d   Fisher, Bernard ^a   Wolmark, Norman ^a  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BLADDER DISEASE; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DYSPNEA; FEMALE; FEVER; FISHER EXACT TEST; FUNCTIONAL ASSESSMENT; GENITAL SYSTEM; HAIR LOSS; HEADACHE; HEALTH SURVEY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MOOD DISORDER; NAUSEA; PAIN; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RATING SCALE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THORAX PAIN; TREATMENT OUTCOME; VOMITING;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HEALTH STATUS; HUMANS; INFUSIONS, INTRAVENOUS; METHOTREXATE; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 3343019255     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000032983.87966.4e     Document Type: Article

References (19)

1. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19(4): 931-942, 2001
2. Fisher B, Brown AM, Dimotrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, Shibata H, Paterson AHG, Sutherland C, Robert N, Ager PJ, Levy L, Wolter J, Wozniak T, Fisher ER, Deutsch M: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from NSABP B-15. J Clin Oncol 8: 1483-1496, 1990
3. Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B: Baseline quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 87: 1372-1382, 1995
4. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B: Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17: 2659-2669, 1999
5. Day R, Ganz PA, Costantino JP: Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 93(21): 1615-1623, 2001
6. Land S, Wieand S, Day R, et al: Methodological issues in the analysis of quality of life data in clinical trials: illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. In: Mesbah M, Cole B, Lee M (eds) Statistical Design, Measurement and Analysis of Health Related Quality of Life. Kluwer Academic Publishers, Dordrecht, The Netherlands, 2002
7. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K, Lloyd S, Purl S, Blendowski C, Goodman M, Barnicle M, Stewart I, McHale M, Bonomi P, Kaplan E, Taylor IV S, Thomas Jr CR, Harris J: Functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11: 570-579, 1993
8. Cella D: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Version 4, Center on Outcomes, Research and Education, Evanston Northwestern Health Care and Northwestern University, Evanston, IL, 1997
9. Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey Manual and Interpretation Guide. QualityMetric, Inc., Lincoln, Rhode Island, 2000
10. Little RJA: A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc 83: 1198-1202, 1988
11. Little RJA, Rubin D: Statistical Analysis with Missing Data. Wiley, New York, 1987
12. Hastie TJ, Tibshirani RJ: Generalized Additive Models. Chapman & Hall, London, 1994
13. Schwarz G: Estimating the dimension of a model. Ann Stat 6:461-464, 1978
14. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G: Reliability and validity of the Functional Assessment of Cancer Therapy - Breast quality-of-life instrument. J Clin Oncol 15(3): 974-986, 1997
15. Joly F, Espié M, Marty M, Heron JF, Henry-Amar M: Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer 83(5): 577-582, 2000
16. Hurny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ: Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347(9011): 1279-1284, 1996
17. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr, Crowley J: Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 81(7): 485-495, 1989
18. Hayden KA, Moinpour CM, Metch B, Feigl P, O'Bryan RM, Green S, Osborne CK: Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum 20(9): 1415-1419, 1993
19. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: Adjuvant systemic therapy for women with node-positive breast cancer. Can Med Assoc J 158(3 Suppl): S52-S64, 1998